<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552279</url>
  </required_header>
  <id_info>
    <org_study_id>109179</org_study_id>
    <nct_id>NCT00552279</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age</brief_title>
  <official_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Romania: National Drug Agency</authority>
    <authority>Italy: Comitato Etico Azienda Ospedaliera Spedali Civili di Brescia</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and
      safety of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an
      alternative dosing schedule as compared to the standard dosing schedule in young female
      subjects aged 15 - 25 years. The Protocol Posting has been updated in order to comply with
      the FDA Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>One month after the third vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>One month after the third vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titer given as geometric mean titer (GMT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>One month after the second vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>One month after the second vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titer given as GMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) period following each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) period following each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During the 30-day (Days 0-29) period following each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs), New Onset Autoimmune Diseases (NOADs), Serious Adverse Events (SAEs), and Medically Significant Conditions (MSCs)</measure>
    <time_frame>During the entire study period (up to Month 18 or up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6.
NOCDs assessed include eg. autoimmune disorders (NOADs), asthma, type I diabetes. MSCs assessed include AEs prompting emergency room visits and physician office visits not related to common illnesses.
An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancies and Their Outcomes</measure>
    <time_frame>During the entire study period (up to Month 18 or Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6
Number of pregnancies and pregnancy outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Completing the 3-dose Vaccination Schedule</measure>
    <time_frame>After the third vaccine dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">805</enrollment>
  <condition>HPV-16/18 Infections and Cervical Neoplasia</condition>
  <arm_group>
    <arm_group_label>Cervarix-12 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix-6 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix TM</intervention_name>
    <description>Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.</description>
    <arm_group_label>Cervarix-12 Group</arm_group_label>
    <other_name>HPV vaccine (GSK580299)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix TM</intervention_name>
    <description>Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Cervarix-6 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parent(s)/Legally
             acceptable representative(s) (LAR) can and will comply with the requirements of the
             protocol

          -  A female between and including 15 and 25 years of age at the time of the first
             vaccination.

          -  Written informed consent obtained from the subject prior to enrolment. For subjects
             below the legal age of consent, written informed consent must be obtained from the
             subject's parents/legally acceptable representative (LAR), and written informed
             assent must be obtained from the subject.

          -  Healthy subjects as established by medical history and/or clinical examination before
             entering into the study.

          -  Subject must be of non-childbearing potential, or if she is of child bearing
             potential, she must practice adequate contraception for 30 days prior to vaccination,
             have a negative urine pregnancy test and continue such precautions for 2 months after
             completion of the vaccination series.

          -  Subject who had no more than 6 lifetime sexual partners prior to enrolment.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after the first dose of vaccine. Planned
             administration/administration of routine vaccines up to 8 days before the first dose
             of study vaccine is allowed. Enrolment will be deferred until the patient is outside
             of specified window.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  previous administration of components of the investigational vaccine

          -  Cancer or autoimmune disease under treatment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Hypersensitivity to latex

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding blood sampling.

          -  Pregnant or breastfeeding female.

          -  Female planning to become pregnant, likely to become pregnant (as determined by the
             investigator) or planning to discontinue contraceptive precautions during the study
             period starting at visit one and up to two months after the last vaccine dose.

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal
             function abnormality as determined by physical examination or lab tests.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodi</city>
        <state>Lombardia</state>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ragusa</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>010507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>077190</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400217</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>026 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nova Dubnica</city>
        <zip>018 51</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </location_countries>
  <reference>
    <citation>Esposito S et al. Human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine administered according to an alternative dosing schedule. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.</citation>
  </reference>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>September 6, 2012</lastchanged_date>
  <firstreceived_date>October 30, 2007</firstreceived_date>
  <firstreceived_results_date>February 12, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>papillomavirus</keyword>
  <keyword>Human papillomavirus (HPV) vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 805 subjects were enrolled and 804 subjects were vaccinated and included in the analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix-12 Group</title>
          <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix-6 Group</title>
          <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix-12 Group</title>
          <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix-6 Group</title>
          <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="403"/>
                <measurement group_id="B2" value="401"/>
                <measurement group_id="B3" value="804"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18.6" spread="2.98"/>
                <measurement group_id="B2" value="18.7" spread="3.13"/>
                <measurement group_id="B3" value="18.6" spread="3.05"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="403"/>
                <measurement group_id="B2" value="401"/>
                <measurement group_id="B3" value="804"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
        <time_frame>One month after the third vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on initially seronegative subjects from the According-to-Protocol (ATP) cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
            <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 (N=337;342)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="337"/>
                  <measurement group_id="O2" value="342"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (N=346;346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="345"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titer given as geometric mean titer (GMT).</description>
        <time_frame>One month after the third vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on initially seronegative subjects from the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Titer given as geometric mean titer (GMT).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 (N=337;342)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11337.2" lower_limit="10238.2" upper_limit="12554.1"/>
                  <measurement group_id="O2" value="10050.9" lower_limit="9180.9" upper_limit="11003.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (N=346;346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4526.7" lower_limit="4110.1" upper_limit="4985.6"/>
                  <measurement group_id="O2" value="3879.9" lower_limit="3532.7" upper_limit="4261.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
        <time_frame>One month after the second vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on initially seronegative subjects from the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination.
Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 (N=337;342)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="337"/>
                  <measurement group_id="O2" value="342"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (N=346;346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titer given as GMT.</description>
        <time_frame>One month after the second vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on initially seronegative subjects from the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Titer given as GMT.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 (N=337;342)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3307.0" lower_limit="3051.0" upper_limit="3584.5"/>
                  <measurement group_id="O2" value="3184.1" lower_limit="2938.3" upper_limit="3450.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (N=346;346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2382.3" lower_limit="2179.2" upper_limit="2604.3"/>
                  <measurement group_id="O2" value="2256.3" lower_limit="2070.7" upper_limit="2458.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.</description>
        <time_frame>During the 7-day (Days 0-6) period following each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                  <measurement group_id="O2" value="401"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="385"/>
                  <measurement group_id="O2" value="386"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="182"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="145"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria.</description>
        <time_frame>During the 7-day (Days 0-6) period following each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                  <measurement group_id="O2" value="401"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="237"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature ≥ 37.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastro-intestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                  <measurement group_id="O2" value="168"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 30-day (Days 0-29) period following each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="403"/>
                  <measurement group_id="O2" value="401"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="117"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs), New Onset Autoimmune Diseases (NOADs), Serious Adverse Events (SAEs), and Medically Significant Conditions (MSCs)</title>
        <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6.
NOCDs assessed include eg. autoimmune disorders (NOADs), asthma, type I diabetes. MSCs assessed include AEs prompting emergency room visits and physician office visits not related to common illnesses.
An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>During the entire study period (up to Month 18 or up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="403"/>
                  <measurement group_id="O2" value="401"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs), New Onset Autoimmune Diseases (NOADs), Serious Adverse Events (SAEs), and Medically Significant Conditions (MSCs)</title>
            <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6.
NOCDs assessed include eg. autoimmune disorders (NOADs), asthma, type I diabetes. MSCs assessed include AEs prompting emergency room visits and physician office visits not related to common illnesses.
An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>MSCs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NOCDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NOADs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancies and Their Outcomes</title>
        <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6
Number of pregnancies and pregnancy outcomes.</description>
        <time_frame>During the entire study period (up to Month 18 or Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort, on pregnant subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Pregnancies and Their Outcomes</title>
            <description>Entire study period = up to Month 18 Cervarix-12 &amp; Month 12 Cervarix-6
Number of pregnancies and pregnancy outcomes.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal infant</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective abortion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abortion threatened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ongoing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Foetal distress syndrome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Completing the 3-dose Vaccination Schedule</title>
        <time_frame>After the third vaccine dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix-12 Group</title>
            <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix-6 Group</title>
            <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="403"/>
                  <measurement group_id="O2" value="401"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Completing the 3-dose Vaccination Schedule</title>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="388"/>
                  <measurement group_id="O2" value="397"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Analysis for other adverse events were performed on the Total vaccinated cohort, on subjects with available data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix-12 Group</title>
          <description>Women received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 12-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix-6 Group</title>
          <description>Women received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="385" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="386" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="385" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="386" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Temperature ≥ 37.5°C</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="402"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
